Artigo

17 Ago 2006

Daniel Rosan, Program Director for Public Health, Interfaith Center on Corporate Responsibility [USA]

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

[Presentation by Daniel Rosan begins at 54:30; refers to Abbott Laboratories, Bristol-Myers Squibb, Merck, Gilead Sciences, Wyeth]

Linha do tempo

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Data:

4 Mar 2014

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
[PDF] Benchmarking AIDS: 2006 Year End Update

Data:

30 Nov 2006

Tipo de conteúdo:

Artigo

Idiomas disponíveis: English
Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Data:

13 Set 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Data:

13 Set 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Data:

13 Set 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Data:

12 Set 2006

Tipo de conteúdo:

Artigo

Idiomas disponíveis: English
Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Data:

6 Set 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Data:

6 Set 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Reclaman mayor compromiso de las farmacéuticas

Data:

31 Ago 2006

Tipo de conteúdo:

Artigo

Idiomas disponíveis: español
Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Data:

23 Ago 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Data:

23 Ago 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

Data:

23 Ago 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

Data:

17 Ago 2006

Tipo de conteúdo:

Artigo

Idiomas disponíveis: English
[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

Data:

17 Ago 2006

Tipo de conteúdo:

Artigo

Idiomas disponíveis: English
New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Data:

14 Ago 2006

Tipo de conteúdo:

Artigo

Idiomas disponíveis: English
Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Data:

1 Ago 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Data:

1 Ago 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Data:

8 Jan 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.

Data:

8 Jan 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English

Veja a história completa

Carregar mais Ver menos

Business & Human Rights
Resource Centre

Centro de Informação sobre Empresas e Direitos Humanos

Esta página não está disponível em Português e está sendo exibida em English

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

Linha do tempo

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

[PDF] Benchmarking AIDS: 2006 Year End Update

Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Reclaman mayor compromiso de las farmacéuticas

Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.